Seagen Aims To Make Tukysa First Drug For HER2-Positive Colorectal Cancer

 
• By Jessica Merrill

The Phase II MOUNTAINEER trial showed a benefit for patients with HER2-positive metastatic colorectal cancer treated with the tyrosine kinase inhibitor in combination with trastuzumab.

number one
Seagen hopes to be first to market with a HER2-targeted treatment for colorectal cancer • Source: Shutterstock

More from Clinical Trials

More from R&D